» Articles » PMID: 15740979

1400W, a Potent Selective Inducible NOS Inhibitor, Improves Histopathological Outcome Following Traumatic Brain Injury in Rats

Overview
Journal Nitric Oxide
Publisher Elsevier
Date 2005 Mar 3
PMID 15740979
Citations 26
Authors
Affiliations
Soon will be listed here.
Abstract

There are conflicting data regarding the role of nitric oxide (NO) produced by inducible NO synthase (iNOS) in the pathophysiology of traumatic brain injury (TBI). In this report, we evaluated the effect of a potent selective (iNOS) inhibitor, 1400W, on histopathological outcome following TBI in a rat model of lateral fluid percussion brain injury. First, to design an appropriate treatment protocol, the parallel time courses of iNOS and neuronal NOS (nNOS) gene expression, protein synthesis, and activity were investigated. Early induction of iNOS gene was observed in the cortex of injured rats, from 6 to 72 h with a peak at 24 h. Similarly, iNOS protein was detected from 24 to 72 h and de novo synthesized iNOS was functionally active, as measured by Ca2+-independent NOS activity. The kinetic studies of nNOS showed discrepancies, since nNOS gene expression and protein synthesis were constant in the cortex of injured rats from 24 to 72 h, while Ca2+-dependent constitutive NOS activity was markedly decreased at 24 h, persisting up to 72 h. Second, treatment with 1400W, started as a bolus of 20 mg kg-1 (s.c.) at 18 h post-TBI, followed by s.c.-infusion at a rate of 2.2 mg kg-1 h-1 between 18 and 72 h, reduced by 64% the brain lesion volume at 72 h. However, the same treatment paradigm initiated 24 h post-TBI did not have any effect. In conclusion, administration of a selective iNOS inhibitor, 1400W, even delayed by 18 h improves histopathological outcome supporting a detrimental role for iNOS induction after TBI.

Citing Articles

Repeated-Dose Toxicity of Lauric Acid and Its Preventive Effect Against Tracheal Hyper-Responsiveness in Wistar Rats with Possible Molecular Targets.

Figueiredo I, Martins A, Cavalcanti A, Fernandes J, Gomes L, Vieira M Pharmaceuticals (Basel). 2025; 18(2).

PMID: 40006035 PMC: 11859213. DOI: 10.3390/ph18020221.


Toll-Like Receptor 1/2 Postconditioning by the Ligand Pam3cys Tempers Posttraumatic Hyperexcitability, Neuroinflammation, and Microglial Response: A Potential Candidate for Posttraumatic Epilepsy.

Khoshkroodian B, Javid H, Pourbadie H, Sayyah M Inflammation. 2024; .

PMID: 39044002 DOI: 10.1007/s10753-024-02109-z.


1400 W, a selective inducible nitric oxide synthase inhibitor, mitigates early neuroinflammation and nitrooxidative stress in diisopropylfluorophosphate-induced short-term neurotoxicity rat model.

Massey N, Vasanthi S, Samidurai M, Gage M, Rao N, Meyer C Front Mol Neurosci. 2023; 16:1125934.

PMID: 37008784 PMC: 10064070. DOI: 10.3389/fnmol.2023.1125934.


Targeting hydrogen sulfide and nitric oxide to repair cardiovascular injury after trauma.

Huerta de la Cruz S, Santiago-Castaneda C, Rodriguez-Palma E, Medina-Terol G, Lopez-Preza F, Rocha L Nitric Oxide. 2022; 129:82-101.

PMID: 36280191 PMC: 10644383. DOI: 10.1016/j.niox.2022.10.003.


Neurotransmitters: Potential Targets in Glioblastoma.

Huang Q, Chen L, Liang J, Huang Q, Sun H Cancers (Basel). 2022; 14(16).

PMID: 36010960 PMC: 9406056. DOI: 10.3390/cancers14163970.